AR061959A1 - Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas - Google Patents

Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas

Info

Publication number
AR061959A1
AR061959A1 ARP070103017A ARP070103017A AR061959A1 AR 061959 A1 AR061959 A1 AR 061959A1 AR P070103017 A ARP070103017 A AR P070103017A AR P070103017 A ARP070103017 A AR P070103017A AR 061959 A1 AR061959 A1 AR 061959A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
contraception
risk
reduce
congenital malformations
Prior art date
Application number
ARP070103017A
Other languages
English (en)
Inventor
Claussen Claus
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06016950A external-priority patent/EP1891959A1/de
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR061959A1 publication Critical patent/AR061959A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Una composición farmacéutica para la anticoncepción contiene en una dosis diaria 2,0 mg. o 1,5 mg. de 17-cianometil-17-b-hidroxi-estra-4,9-dien-3-ona (dienogest) y 0,015 mg. de 17-etinilestradiol (etinilestradiol) y (6S)-5-metiltetrahidrofolato, con preferencia como sal de calcio del ácido (6S)-5-metiltetrahidrofólico (metafolina) junto con uno o varios excipientes/vehículos farmacéuticamente aceptables. La composición farmacéutica realiza una anti-concepción oral y es también un agente para reducir el riesgo de malformaciones congénitas. Por otra parte, un kit contiene 21 unidades de dosis diarias de la composición farmacéutica y 7 unidades de dosis diarias que contienen solo (6S)-5-metiltetrahidrofolato, incluso con preferencia metafolina.
ARP070103017A 2006-07-06 2007-07-06 Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas AR061959A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06014002 2006-07-06
EP06016950A EP1891959A1 (de) 2006-08-14 2006-08-14 Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen

Publications (1)

Publication Number Publication Date
AR061959A1 true AR061959A1 (es) 2008-08-10

Family

ID=38330771

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103017A AR061959A1 (es) 2006-07-06 2007-07-06 Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas

Country Status (16)

Country Link
US (1) US20080268048A1 (es)
EP (1) EP2037935A1 (es)
JP (1) JP2009542588A (es)
KR (1) KR20090029824A (es)
AR (1) AR061959A1 (es)
BR (1) BRPI0713999A2 (es)
CA (1) CA2665788A1 (es)
CL (1) CL2007001961A1 (es)
DE (1) DE112007001600A5 (es)
IL (1) IL196154A0 (es)
MX (1) MX2009000256A (es)
PE (1) PE20080400A1 (es)
RU (1) RU2009102443A (es)
TW (1) TW200810764A (es)
UY (1) UY30461A1 (es)
WO (1) WO2008003363A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
RS61812B1 (sr) 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetriol
MY195019A (en) 2015-06-18 2023-01-03 Estetra Sprl Orodispersible dosage unit containing an estetrol component
PL3310346T3 (pl) 2015-06-18 2021-10-25 Estetra Sprl Dyspergowalna w ustach tabletka zawierająca estetrol
RS62844B1 (sr) 2015-06-18 2022-02-28 Estetra Srl Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
JP2002512185A (ja) * 1998-04-17 2002-04-23 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 葉酸を含有する製薬学的組成物並びに関連する方法及び送達系
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US7696219B2 (en) * 2000-09-27 2010-04-13 Everett Laboratories, Inc. Method and composition for supplementation of nutritional deficiences in renal patients
US20020147155A1 (en) * 2001-04-06 2002-10-10 Foster Warren G. Prevention and treatment of endometriosis with aryl hydrocarbon receptor binding ligands
DK1478373T3 (da) * 2002-02-21 2007-01-15 Schering Ag Farmaceutisk præparat omfattende ét eller flere steroider, én eller flere tetrahydrofolatbestanddele og vitamin B 12
EP1755562B1 (de) * 2004-05-28 2013-10-09 Richter Gedeon Nyrt. Folsäurehaltiges kontrazeptivum
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.

Also Published As

Publication number Publication date
RU2009102443A (ru) 2010-08-20
CL2007001961A1 (es) 2008-01-11
WO2008003363A1 (de) 2008-01-10
DE112007001600A5 (de) 2009-04-30
KR20090029824A (ko) 2009-03-23
EP2037935A1 (de) 2009-03-25
UY30461A1 (es) 2008-02-29
IL196154A0 (en) 2009-09-22
JP2009542588A (ja) 2009-12-03
CA2665788A1 (en) 2008-01-10
US20080268048A1 (en) 2008-10-30
PE20080400A1 (es) 2008-07-04
TW200810764A (en) 2008-03-01
BRPI0713999A2 (pt) 2012-11-20
MX2009000256A (es) 2009-02-18

Similar Documents

Publication Publication Date Title
AR061959A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
MY169516A (en) Pharmaceutical composition containing a tetrahydrofolic acid
PE20061415A1 (es) Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
ES2525497T3 (es) Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
RS51563B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ROOSUVASTATIN CALCIUM
PE20070192A1 (es) Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
UY33343A (es) Formas de dosificación sólidas orales con dosis muy bajas para la hrt
NZ605176A (en) Pharmaceutical composition comprising drospirenone and contraceptive kit
AR065816A1 (es) Regimen anticonceptivo oral
AR049196A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
AR056694A1 (es) Uso de valerato de estradiol en combinacion con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepcion oral
NO20072687L (no) Farmasoytisk prevensjonspreparat
DOP2007000117A (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
CR10912A (es) Preparacion framaceutica para reducir la endometriosis
DOP2007000122A (es) Forma farmacologica peroral para anticoncepcion
DE60312642D1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
UY29378A1 (es) Preparación farmaceutica para la anticoncepción oral
AR064602A1 (es) Nebulizador anticonceptivo oral
PE20091020A1 (es) Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa
PE20091695A1 (es) COMBINACION FARMACEUTICA DE DROSPIRENONA Y 17ß-ESTRADIOL
RS50849B (sr) Upotreba estradiolvalerata i dienogesta za oralno lečenje disfunkcionalnog uterinog krvarenja u kontracepcijskom metodu
CR9240A (es) Forma farmacologica peroral solida para la anticoncepcion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal